Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]
This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors [Phase 1]
Phase 1 update reporting safety, pharmacokinetics, and preliminary efficacy data for AI-061 in advanced solid tumors across multiple indicat…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors [Phase 2]
Jazz Pharmaceuticals is conducting a Phase 2 trial of Zanidatamab in HER2-expressing tumors across multiple cancers. The study is currently …
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) [Phase 3]
A Phase 3 trial comparing GME751 to pembrolizumab (Keytruda) in adults with untreated metastatic non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers [Phase 1]
Phase Ib trial evaluating adagrasib (KRAS G12C inhibitor) in combination with olaparib in KRAS G12C-mutated advanced solid tumors, focusing …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC [Phase 2]
Phase 2 trial results of IO102-IO103 in combination with pembrolizumab as first-line therapy for metastatic non-small cell lung cancer, head…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) [Phase 2]
Phase 2 study compares subcutaneous pembrolizumab coformulated with hyaluronidase alfa (MK-3475A) to intravenous pembrolizumab in multiple t…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors [Phase 1, Phase 2]
GEN1042 is being evaluated in a Phase 1/2 safety study with indications across malignant solid tumors, including non-small cell lung cancer,…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors [Phase 1]
Phase 1 study update for RMC-6291 monotherapy in KRASG12C-mutant solid tumors, outlining dose-escalation and dose-expansion cohorts in subje…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
This clinical trial update describes a Roche-sponsored Phase 1/2 study in non-small cell lung cancer to evaluate how well and how safely dif…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors [Phase 1]
A Phase 1 study of Inlexisertib (DCC-3116) in patients with RAS/MAPK pathway mutant solid tumors, including Non-Small Cell Lung Cancer, has …
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) [Phase 3]
Phase 3 trial to evaluate acasunlimab plus pembrolizumab vs docetaxel in PD-L1-positive non-small cell lung cancer is currently active but n…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study [Phase 2]
A Phase II trial of JS212 plus JS111 for EGFR-mutant non-small cell lung cancer is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
This document summarizes a real-world evaluation of sotorasib in Chinese patients with non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. [Phase 4]
A Phase 4 trial evaluating capmatinib in Indian patients with MET exon 14 skipping mutation–positive advanced non-small cell lung cancer has…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer [Phase 3]
A Phase 3 study evaluating romiplostim for chemotherapy-induced thrombocytopenia in adults with non-small cell lung cancer, ovarian cancer, …
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 [Phase 2]
Update on a Phase 2 study of disitamab vedotin in HER2-expressing solid tumors, currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
This update announces the availability of an Expanded Access Program for Neladalkib (NVL-655) for patients with advanced ALK-positive non-sm…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
A completed real-world study assesses whether concurrent beta-blocker use affects outcomes for patients with advanced non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer [Phase 1]
A Phase 1 study assessing RAD001 (everolimus) in combination with radiotherapy for non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating maintenance olaparib in platinum-sensitive advanced non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 [Phase 1, Phase 2]
A Phase 1/2 trial evaluating ChAdOx1 and MVA vaccines targeting MAGE-A3 and NY-ESO-1 for non-small cell lung cancer and esophageal squamous …
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating STEMVAC, a multiple antigen vaccine, for Stage IV non-small cell lung cancer. The study is active not recruiting …
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis [Phase 2]
A Phase 2 trial evaluated high-dose furmonertinib in combination with bevacizumab and intrathecal pemetrexed for EGFR-mutated metastatic non…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/Phase 2 trial results for the combination of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) with tislelizumab in advanced solid …